Our New Drug and Diagnostic Approach Could Be Used for at Least Five Types of Cancers
Type of Cancer
Number of Diagnoses in the U.S. per Year
|Acute Myeloid Leukemia (AML)||21,380|
|Myelodysplastic Syndromes (MDS)||10,000+|
|Triple Negative Breast Cancer||34,776|
|Non-Small Cell Lung Cancer||224,000|
These cancers have shown potential sensitivity to our drug and have few targeted therapies currently available. AML and MDS showed the highest sensitivity so we are focusing on those first.
Sources: Cowen and Company. Therapeutic Categories Outlook. October 2014; SEER.Cancer.gov, Nov. 2015; and Needham and Company. AML Drug Development Update, April 2016.